To protect from COVID-19 pandemic, several vaccines were developed infection with expected immunity against a SARS-CoV-2 infection. Short time side effects are reported. New onset diabetes was reported after SARS-CoV-2 infection. Here we report a case of new onset diabetes presenting with hyperosmolar hyperglycemic state, whose symptoms followed right after the second dose of Pfizer-BioNTech COVID-19 Vaccine. He is a 56-year old, obese Afro-American Veteran with no family history of diabetes and with HbA1C of 5.6 forty-five days prior to the hospitalization. He noted polyurea and excessive thirst following the second dose Pfizer-BioNTech COVID-19 vaccine. Hospitalized with hyperosmolar state and HbA1C of more than 14, he was treated initially with insulin drip and changed to basal, bolus regimen. In addition, he had new onset of oral thrush, requiring antifungal therapy. He needed higher doses of insulin during hospitalization and at discharge. He rapidly recovered and could be tapered off insulin in 4 months and recovered to normal glycemic state. We conclude that this is the second state to present with hyperosmolar state, and first case with rapid recovery of glycemic state.
References
[1]
Kempegowda, P., Melson, E., Johnson, A., Wallett, L., Thomas, L., Zhou, D., et al. (2021) Effect of COVID-19 on the Clinical Course of Diabetic Ketoacidosis (DKA) in People with Type 1 and Type 2 Diabetes. Endocrine Connections, 10, 371-377. https://doi.org/10.1530/EC-20-0567
[2]
Reddy, P.K., Kuchay, M.S., Mehta, Y. and Mishra, S.K. (2020) Diabetic Ketoacidosis Precipitated by COVID-19: A Report of Two Cases and Review of Literature. Diabetes & Metabolic Syndrome, 14, 1459-1462. https://doi.org/10.1016/j.dsx.2020.07.050
[3]
Schmitt, J., Rahman, A.F. and Ashraf, A. (2020) Concurrent Diabetic Ketoacidosis with Hyperosmolality and/or Severe Hyperglycemia in Youth with Type 2 Diabetes. Endocrinology, Diabetes & Metabolism, 3, Article ID: e00160. https://doi.org/10.1002/edm2.160
[4]
Chamorro-Pareja, N., Parthasarathy, S., Annam, J., Hoffman, J., Coyle, C. and Kishore, P. (2020) Letter to the Editor: Unexpected High Mortality in COVID-19 and Diabetic Ketoacidosis. Metabolism, 110, Article ID: 154301. https://doi.org/10.1016/j.metabol.2020.154301
[5]
Palermo, N.E., Sadhu, A.R. and McDonnell, M.E. (2020) Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations. The Journal of Clinical Endocrinology & Metabolism, 105, 2819-2829. https://doi.org/10.1210/clinem/dgaa360
[6]
Mondal, S., DasGupta, R., Lodh, M., Gorai, R., Choudhury, B., Hazra, A.K., et al. (2021) Predictors of New-Onset Diabetic Ketoacidosis in Patients with Moderate to Severe COVID-19 Receiving Parenteral Glucocorticoids: A Prospective Single-Centre Study among Indian Type 2 Diabetes Patients. Diabetes & Metabolic Syndrome, 15, 795-801. https://doi.org/10.1016/j.dsx.2021.03.022
[7]
Aabdi, M., Aarab, A., Es-Saad, O., Malki, K., Bkiyar, H. and Housni, B. (2021) New-Onset Diabetes in Children during COVID-19: Clinical Case Report. Case Reports in Endocrinology, 2021, Article ID: 6654019. https://doi.org/10.1155/2021/6654019
[8]
Sathish, T. and Cao, Y. (2021) Is Newly Diagnosed Diabetes as Frequent as Preexisting Diabetes in COVID-19 Patients? Diabetes & Metabolic Syndrome, 15, 147-148. https://doi.org/10.1016/j.dsx.2020.12.024
[9]
Naguib, M.N., Raymond, J.K. and Vidmar, A.P. (2021) New Onset Diabetes with Diabetic Ketoacidosis in a Child with Multisystem Inflammatory Syndrome Due to COVID-19. Journal of Pediatric Endocrinology and Metabolism, 34, 147-150. https://doi.org/10.1515/jpem-2020-0426
[10]
Sathish, T., Tapp, R.J., Cooper, M.E. and Zimmet, P. (2021) Potential Metabolic and Inflammatory Pathways between COVID-19 and New-Onset Diabetes. Diabetes & Metabolism, 47, Article ID: 101204. https://doi.org/10.1016/j.diabet.2020.10.002
[11]
Singh, A.K. and Singh, R. (2020) Hyperglycemia without Diabetes and New-Onset Diabetes Are Both Associated with Poorer Outcomes in COVID-19. Diabetes Research and Clinical Practice, 167, Article ID: 108382. https://doi.org/10.1016/j.diabres.2020.108382
[12]
Gentile, S., Strollo, F., Mambro, A. and Ceriello, A. (2020) COVID-19, Ketoacidosis and New-Onset Diabetes: Are There Possible Cause and Effect Relationships among Them? Diabetes, Obesity and Metabolism, 22, 2507-2508. https://doi.org/10.1111/dom.14170
[13]
Suwanwongse, K. and Shabarek, N. (2021) Newly Diagnosed Diabetes Mellitus, DKA, and COVID-19: Causality or Coincidence? A Report of THREE cases. Journal of Medical Virology, 93, 1150-1153. https://doi.org/10.1002/jmv.26339
[14]
Rubino, F., Amiel, S.A., Zimmet, P., Alberti, G., Bornstein, S., Eckel, R.H., et al. (2020) New-Onset Diabetes in Covid-19. New England Journal of Medicine, 383, 789-790. https://doi.org/10.1056/NEJMc2018688
[15]
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G. and Van Goor, H. (2004) Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis. Journal of Pathology, 203, 631-637. https://doi.org/10.1002/path.1570
[16]
Yang, J.K., Lin, S.S., Ji, X.J. and Guo, L.-M. (2010) Binding of SARS Coronavirus to Its Receptor Damages Islets and Causes Acute Diabetes. Acta Diabetologica, 47, 193-199. https://doi.org/10.1007/s00592-009-0109-4
[17]
Coate, K.C., Cha, J., Shrestha, S., Wang, W., Gonçalves, L.M., Almaça, J., et al. (2020) SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in β Cells. Cell Metabolism, 32, 1028-1040 e4. https://doi.org/10.1016/j.cmet.2020.11.006
[18]
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., et al. (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383, 2603-2615. https://doi.org/10.1056/NEJMoa2034577
[19]
Abu-Rumaileh, M.A., Gharaibeh, A.M. and Gharaibeh, N.E. (2021) COVID-19 Vaccine and Hyperosmolar Hyperglycemic State. Cureus, 13, Article ID: e14125. https://doi.org/10.7759/cureus.14125
[20]
Parkash, O., Sharko, A., Farooqi, A., Ying, G.W. and Sura, P. (2021) Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine. Cureus, 13, Article ID: e14741. https://doi.org/10.7759/cureus.14741
